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ABSTRACT 
Osseointegration of Temporary Anchorage Devices Using Recombinant  
Human Bone Morphogenetic Protein-2 
Erin E. Cruz 
 
 
Over the past 5 years, the use of titanium implants as temporary anchorage 
devices (TADs) has become an important tool in clinical orthodontic practices.  The 
use of TADs have provided orthodontists a way of moving teeth against fixed objects 
rather than against the surrounding teeth, which tend to counteract desired motion.  At 
present, viable attachment of TADs involves direct insertion through gingival tissue 
and piercing of the bone.  Surface modifications such as sandblasted and acid-etched 
treatment or bone morphogenetic protein surface treatment, however, can be applied 
to the TADs to promote enhanced osseointegration, thereby allowing the TADs to 
serve as stable anchors while avoiding bone puncture.  In this study, a comparison 
was made between sandblasted/acid-etched TADs and sandblasted/acid-
etched/recombinant human bone morphogenetic protein-2 (rhBMP-2) treated TADs 
to determine whether rhBMP-2 promotes enhanced osseointegration.  A total of 10 
rats (4 controls and 6 treated with rhBMP-2) were used in the study, with 1 TAD 
placed on the skull of each rat.  At the end of 6 weeks, the animals were euthanized 
by carbon dioxide asphyxiation, and bone blocks, each containing a TAD, were 
prepared for histological examination and biomechanical characterization.  The 
results of this study showed that TADs treated with rhBMP-2 had greater bone 
formation at the bone-implant interface and an increase in total implant stability. 
 
Keywords:  recombinant human bone morphogenetic protein-2 (rhBMP-2), 
osseointegration, temporary anchorage device, sandblasted and acid etched, titanium 
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1.  LITERATURE REVIEW 
For more than 40 years, titanium has been widely used as a biocompatible implant 
material for dental applications.  In general and prosthetic dentistry, titanium implants 
today have become a regular and customary alternative to one or more missing teeth. 
Orthodontics, however, has been slow in using this important tool as a temporary anchor. 
It has only been in the last 5 years that an explosion of temporary anchorage devices 
(TADs) has appeared in clinical orthodontic practices.  
 
During orthodontic treatment, TADs control tooth movement by preventing 
unwanted or allowing desired dental movement [1].  In orthodontics, the difficulty that 
usually arises when moving teeth is that the surrounding teeth tend to counteract the 
desired motion.  This is consistent with Newton’s third law, which states that for every 
action, there is an equal and opposite reaction.  However, instead of using molars as 
anchors, which may facilitate movement of the teeth (action / reaction forces) as defined 
by Newton’s third law, the use of TADs allows teeth to be moved against fixed objects 
rather than against the surrounding teeth.  Therefore, TADs provide orthodontists and 
patients with appealing treatment alternatives to restorative and surgical procedures.  
 
Although TADs show great potential in orthodontic practice, they also introduce 
possible serious risks to the anatomical structures of the maxillary and mandibular bones.  
If there is inadequate amount of bone available at the implant site or insufficient space to 
insert TADs that are 5 to 12 mm in length and 1.3 to 2 mm in diameter, then the roots of 
the adjacent teeth, soft tissue, sinus and nasal cavities, and neurovascular bundles could 
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be damaged [2, 3].  At present, viable attachment of TADs involves direct insertion 
through the gingival tissue and piercing of the bone.  Unfortunately, bone puncture may 
induce bone infections, such as localized or systemic osteomyelitis.  In addition, when 
considering the roots of the teeth, a bone piercing TAD would be limited in terms of 
insertion site.  With a bone piercing TAD, the TAD would have to be placed between the 
roots in order to avoid injury to the roots or other anatomical structures nearby.  With this 
in mind, would it be possible to get the undersurface of a TAD to adhere to bone and thus 
avoid the undesirable side effects associated with bone piercing?   
 
In 1995, Block and Hoffman developed a disc-like structure called an “onplant,” 
which required less bone depth compared to the usual endosseous (contained within 
bone) implants.  The onplant is a hydroxyapatite-coated titanium alloy disk that is 10 mm 
in diameter and 2 mm high (refer to Fig. 1) and placed on the palatal bone to provide 
anchorage for orthodontic tooth movement [3].  Through experimentation, Block and 
Hoffman found that the onplant, after subjected to orthodontic forces, provided total 
anchorage for tooth movement without reciprocal movement of the onplant [3, 4].  In 
addition, the onplant prevented anterior dental retraction by providing maximum 
anchorage to molars [3, 4].  However, a disadvantage of the onplant is the complications 
that occur with the removal process.  During the removal of the onplant, a large portion 
of soft tissue must be re-exposed, which could be uncomfortable for the patient.  
Although the onplant takes bone height into account and avoids the risks involved with 
bone perforation, the removal technique introduces invasive procedures.  Would it be 
possible to avoid piercing the bone and develop a removal technique that is less-invasive? 
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Surface TADs could provide a way to minimize the discomfort associated with the 
removal process while avoiding puncture of the bone.  However, surface TADs introduce 
limitations as well.  Compared to longer and wider implants, surface TADs make it more 
difficult to achieve mechanical retention.  Knowing this, how could the bone-to-TAD 
interface be strengthened in order to attain the mechanical retention desired?   
 
 
Figure 1-1 – Picture of an Onplant 
Taken from The Role of Implants in Orthodontic by S.F.H. Ismail and A.S. Johal 
 
Per Ingvar Branemark first coined the term osseointegration when a titanium 
cylinder used in one of his experiments had integrated tightly into rabbit bone.  More 
specifically, osseointegration is defined as the direct structural and functional connection 
between living bone and the surface of an implant.  Bone-compatible materials such as 
titanium, titanium alloys, and hydroxyapatite, have been shown to achieve 
osseointegration [4].  Presently, osseointegrated implants are used to treat both 
completely edentulous (being without teeth) and partially edentulous ridges.  In addition, 
osseointegration makes it possible to increase orthodontic anchorage because an implant 
directly integrated into bone should not move in response to orthodontic loads [4].  
Therefore, through osseointegration, a TAD made of titanium could serve as a stable 
anchor. 
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For this study, titanium is chosen as the dental implant material because it has 
excellent biocompatibility, is strong and lightweight, and is highly resistant to corrosion, 
stress, and fracture [5, 6, 7, 8].  Titanium has been used for both endosseous and 
subperiosteal implants for many years.  In addition, titanium easily passivates to form a 
protective oxide layer, which allows the apposition of proteins and tissue to the metal 
surface [7].  Thus, titanium itself promotes osseointegration because direct contact occurs 
between the bone and the implant surface [7, 9].  Although other materials, such as gold 
and platinum, have shown to be corrosion resistant, their low tensile strength makes 
titanium a better choice of implant material.  Furthermore, stainless steel has also been 
used in orthodontic practice because of its resistance to corrosion and its high strength.  
Its high corrosion resistance is due to its low carbon and sulfur content and its high 
chromium and nickel content.  Unfortunately, nickel is not a biocompatible material and 
has shown to cause allergic reactions [5].  On the other hand, titanium is well tolerated by 
the human body.  Therefore, titanium’s physical and mechanical properties, along with its 
ability to integrate into bone, make it an advantageous implant material.   
 
According to previous studies, the surface of an implant has been a determining 
factor for successful osseointegration (direct bond between living bone and the surface of 
an implant), and in particular, microrough titanium surfaces have facilitated enhanced 
bone formation and implant stability [9, 10, 11, 12, 13].  The combination of a 
sandblasted and acid-etched surface has improved bone apposition [9, 10, 12] and 
resulted in higher torque values during biomechanical testing [10, 11, 12]. What if, 
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however, it was possible to increase osseointegration even more? This could lead to 
enhanced implant coverage by bone as well as an increase in adhesion strength at the 
bone-to-implant interface. Therefore, if appropriate surface modifications can be applied 
to the TADs to promote enhanced osseointegration, the TADs could serve as stable 
anchors while avoiding puncture of the bone. With enhanced osseointegration, the TADs 
could develop higher levels of mechanical resistance and stability.  
 
One type of surface modification involves the use of bone morphogenetic protein 
(BMP). BMPs belong to a family of growth factors and are known for their pivotal role in 
cartilage and bone formation [14, 15, 16, 17, 18]. For decades, BMPs have been studied 
because of their ability to heal bone while reducing or eliminating the need to harvest 
bone from other parts of the body. So far, a total of 20 BMPs have been discovered, eight 
(BMP-2 through BMP-9) of which are members of the transforming growth factor-ß 
(TGF-ß) superfamily of proteins. Of these eight, BMP-2 and BMP-7 have gained the 
most attention in regards to therapeutic procedures to treat a variety of skeletal conditions 
and defects. BMP-2 and BMP-7 have demonstrated the greatest osteogenic capacity by 
influencing the differentiation of mesenchymal cells to chondroblasts and osteoblasts 
[16]. Experimental studies have shown the importance of BMP-2 and BMP-7 in bone 
development and the development of a variety of tissues outside of bone [14, 17].  
 
By understanding the important role that BMP plays in cell growth and 
differentiation, scientists have been able to create a genetically engineered version of this 
naturally occurring protein called recombinant human bone morphogenetic protein 
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(rhBMP). More importantly, a large number of preclinical studies have verified the 
ability of rhBMPs to initiate bone growth [16, 17, 18, 19, 20]. In particular, rhBMP-2 has 
been studied more than any other BMP and has received Food and Drug Administration 
(FDA) approval for human clinical uses, such as oral, spinal, and tibial surgeries. The 
local application of rhBMP-2, in addition to a variety of carriers such as a collagen 
sponge, has demonstrated the ability to regenerate skull and mandibular defects [15, 17], 
enhance periodontal new bone formation [15, 16], improve spinal fusion [15, 16, 18, 19, 
21], treat a variety of bone-related conditions such as delayed union and non-union [18], 
and promote fracture repair [15, 18, 19].  
 
For this present study, rhBMP-2 is chosen because of its effectiveness in 
stimulating bone growth in a variety of applications. Specifically, INFUSE® Bone Graft 
(Medtronic Sofamor Danek, Memphis, TN), which consists of rhBMP-2 in combination 
with an absorbable collagen sponge (ACS), is used. Medtronic INFUSE® Bone Graft has 
helped in the spine by promoting the fusion of vertebral bodies to alleviate back pain. It 
has also helped to heal broken bones for tibial fractures, and been used for oral and 
maxillofacial bone grafting procedures, such as sinus augmentation and localized alveolar 
ridge augmentation. Even though studies have validated the effectiveness of the rhBMP-
2/ACS in stimulating new bone growth, it is still important to participate in further 
studies which will expand knowledge of its use and application.   
 
For rhBMP-2 to enhance osseointegration, the implant must be stabilized. 
Without implant stability, there is a risk of microfractures at the implant-bone interface, 
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which could decrease the likelihood of osseointegration. Therefore, it is important for 
TAD stability to exist before and until osseointegration can be obtained. When a simple 
screw TAD is threaded into bone, mechanical resistance can serve as the necessary 
stabilizer until osseointegration occurs. Mechanical resistance and stability is achieved 
because when a force is applied to a body (i.e. tooth) to the left and produces a 
counterclockwise moment about a center of resistance (i.e. screw TAD), an opposite 
system counteracts with a force to the right and a moment in the clockwise direction [4]. 
This means that the sum of all forces equals zero, and the sum of all moments about a 
point is also zero. Thus, the screw TAD achieves static equilibrium.  
 
However, when the goal is to avoid bone puncture by surface osseointegration, 
what means of stabilization can be employed to ensure that the TAD is stabilized until 
osseointegration can be achieved?  Since the Vietnam War, cyanoacrylate glues have 
been used in medical procedures to seal soft tissue wounds.  There are a variety of 
cyanoacrylates, and each is appropriate for different applications.  For instance, methyl 
cyanoacrylates have the most rigid polymer matrix and are excellent for metal-bonding 
applications.  On the other hand, ethyl cyanoacrylates work well on plastics and 
elastomeric substrates [22].  Butyl cyanoacrylate, in particular, has been tolerated by 
mammalian tissues and used as a surface dressing at oral wounds of both animals and 
human beings [23].  In addition, butyl cyanoacrylate has also shown to reduce edema and 
cause minimal tissue response. Using cyanoacrylate to adhere TADs to the bone is very 
important to the success of this study because achieving TAD stability is essential for 
osseointegration to be obtained.    
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2.   RESEARCH & SPECIFIC AIMS 
2.1     Objective 
The goal of this study is to examine the viability of a combination of existent 
technologies, which include temporary anchorage devices (TADs), 
sandblasted and acid etched surface treatment, bone morphogenetic protein 
surface treatment, and cyanoacrylates.  In particular, the goal is to evaluate 
the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) 
on the ability of TADs to osseointegrate. A comparison will be made 
between sandblasted/acid-etched TADs and sandblasted/acid-etched/rhBMP-
2 treated TADs to determine whether rhBMP-2 promotes enhanced 
osseointegration. Specifically, this research will determine the influence of 
Medtronic INFUSE® Bone Graft on implant anchorage and increased bone 
formation.  Finding a way to enhance bone formation and strengthen bone-to-
TAD contact (increased implant stability) is important because there is a 
significant clinical benefit to patients if a new type of TAD that does not 
pierce the bone is available.  Not only can teeth movement be controlled 
without causing movement to the surrounding teeth, but enhanced bone 
formation at the implant site can prevent bone puncture and serious side 
effects.  
 
2.2     Specific Aim  
To investigate the influence of recombinant human bone morphogenetic 
protein-2 (rhBMP-2) on the osseointegration of temporary anchorage devices 
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(TADs). This will involve qualitatively examining surface topography and 
the amount of the TAD surface covered by bone through photographs and 
visual inspection.  The bone formation on a sandblasted/acid-etched/rhBMP-
2 treated TAD will be compared with bone formation on a sandblasted/acid-
etched control specimen. In addition, biomechanical testing will be done 
using a micromechanical testing system to determine if the rhBMP-2 
treatment on the TAD produces any significant changes in the bond strength 
between the TAD and the bone.  
 
2.3     Hypothesis 
 Sandblasted and acid-etched temporary anchorage devices (TADs) treated 
with recombinant human bone morphogenetic protein-2 (rhBMP-2) will 
promote better osseointegration than TADs that are only sandblasted and 
acid-etched. Specifically, TADs treated with rhBMP-2 on top will show an 
increase in bone formation (implant surface covered by bone) and an increase 
in total implant stability (adhesion strength at the bone-to-TAD interface).  
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3.   MATERIALS & METHODS 
3.1   Subjects  
3.1.1    Guidelines 
Ten adult Sprague-Dawley rats (4 controls and 6 treated with the 
absorbable collagen sponge/rhBMP-2 mixture) with an average 
weight of 450 ± 70 grams were used in this study.  The rats were 
handled in accordance with National Institutes of Health (NIH) 
guidelines for the care and use of laboratory animals (NIH publication 
85-23, Rev. 1985) and the surgeries were performed with the 
approval of the Animal Care and Use Committee (IACUC) of 
California Polytechnic State University, San Luis Obispo.  The details 
of each rat surgery (i.e. time of injection, start time of surgery, end 
time of surgery, etc.) were recorded in a lab notebook. A copy of this 
raw data is found in Appendix A.  
 
3.1.2    Rationale for Species and Numbers 
The Sprague-Dawley rat was selected as the appropriate species 
choice for this study due to its genetic similarity to humans and its 
ability to serve as a general model for the study of human health and 
disease.  Sprague-Dawley rats are widely used for experimental 
purposes, and in particular, their calmness and ease of handling make 
them the choice of species for this study.  Studies similar to this 
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current study have shown sound scientific results with the use of 
Sprague-Dawley rats.  
 
Using a 1-Sample t-test, 10 rats (4 controls and 6 treated with the 
absorbable collagen sponge/rhBMP-2 mixture) were chosen for this 
study so that a sufficient amount of data is produced while limiting 
the number of rats to be used.   
 
3.2    Implant Preparation 
The temporary anchorage devices (TADs) used in this study are manufactured 
from commercially pure titanium and are divided into 2 types of treatments: 
Type 1 is sandblasted (with grit) and acid-etched (combination of anorganic 
acids, HCl/H2SO4 acid bath), and Type 2 is treated with Medtronic INFUSE® 
Bone Graft (recombinant human bone morphogenetic protein-2 placed on an 
absorbable collagen sponge) in addition to being sandblasted and acid-etched.  
For a type 1 treated TAD, a 1 cm x 1 cm absorbable collagen sponge with 
0.09cc of saline will be placed on top of the sandblasted and acid-etched 
implant to serve as the control.  Refer to Figures 3-1 and 3-2 below.   
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Figure 3-1 – Wetting 1 cm x 1 cm            Figure 3-2 – Wetted Collagen     
Collagen Sponge with 0.09cc of               Sponge Placed on Top of   
Saline                                                        Control TAD 
 
For a type 2 treated TAD, a 1 cm x 1 cm absorbable collagen sponge with 
0.09 cc of reconstituted rhBMP-2 will be placed on top of the TAD to serve as 
the rhBMP-2 treated TAD.  The collagen sponge with saline is used so that 
the only variable between the type 1 TAD and the type 2 TAD is the 
reconstituted rhBMP-2.  The collagen sponge must be soaked in the saline or 
rhBMP-2 for at least 15 minutes before it is used. 
 
3.3   Surgical Procedures 
3.3.1    General 
During preliminary experimentation, one rat was used to evaluate the 
following: 1) Effectiveness of the anesthesia (Ketamine, Xylazine, 
Buprenorphine), 2) Instrumentation needed to perform the surgical 
procedure, 3) Pre-operative, operative, and post-operative guidelines, 
4) Type and location of incision, 5) Implant contour, adhesion 
method, closure of incision site, and 6)  Implant size and protruding 
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length.  Details of this preliminary experiment can be found in 
Appendix B.  The actual surgical procedures performed for this study 
were completed based on the findings from the preliminary 
experiments.  In addition, a Surgical Checklist which is found in 
Appendix C was created to ensure that all materials and instruments 
were in the surgical suite at the time of surgery, and that no 
procedural steps were missed.  
  
3.3.2     Pre-Operative 
The instruments used during the procedure were sterilized by heat 
sterilization prior to prep and surgery.  The following instruments 
were sterilized:  a tray for rhBMP-2 procedures, forceps, fine forceps, 
ultrafine forceps, scissors, scalpel, butyl cyanoacrylate applicator, 
glass slab for butyl, surgical drapes, syringes, gloves, Petri dish with 
saline, cotton gauze, and cotton swabs.  Once the instruments were 
sterilized, they were brought to the surgical suite along with other 
materials/equipment such as butyl cyanoacrylate, tupperware for 
weighing the rat, isolation mask and cap, sterile gowns, bench covers, 
weight boat, and the rat in its cage.   
 
Once all the instruments and equipment were available in the surgical 
suite, the assistant prepared the absorbable collagen sponge (ACS) for 
use in surgery.  In preparation for surgery that used a control TAD, 
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0.09cc of saline was placed on a 1cm x 1 cm ACS using a syringe and 
sterile tray. Likewise, in preparation for surgery that used an rhBMP-
2 treated TAD, 0.09cc of reconstituted rhBMP-2 was placed on a 1cm 
x 1 cm ACS using a syringe and sterile tray. The collagen sponge was 
soaked in the saline (or rhBMP-2) for at least 15 minutes.  
Preliminary experiments were done to determine the appropriate size 
of ACS and the amount of rhBMP-2 required for each implant, as 
well as the best tool for cutting the sponge and the best method for 
shaping the sponge during the procedure.  Details of these 
experiments can be found in Appendix D.   
 
While the ACS soaked in either saline or rhBMP-2, the rat was 
weighed to determine the appropriate dosages of Ketamine, Xylazine, 
and Buprenorphine to be administered to the rat.  The rat was placed 
on a bench cover and a mixture of Ketamine and Xylazine (44 mg/kg 
body weight of Ketamine, 10 mg/kg body weight of Xylazine) was 
used for inducing general anesthesia. This provided approximately 30 
minutes of effective anesthesia.  A ½ dose was readily available for 
surgeries that took longer than expected.  The source used to 
determine these dosages was Lumb and Jones Veterinary Anesthesia 
and Analgesia, 4th Ed. by W. J. Tranquilla. In addition, a dose of 
Buprenorphine was administered subcutaneously (0.01 – 0.05 mg/kg 
body weight) between the shoulder blades for pain mitigation [24].  
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The rat was then placed in a chamber until the anesthesia took effect 
and the animal was down.  The table in Appendix E shows the 
number of mL of each drug that should be administered based on the 
rat’s weight.  The dosages were recorded in a lab notebook which is 
under lock and key at the California Polytechnic State University, San 
Luis Obispo surgical suite.  The Ketamine/Xylazine and 
Buprenorphine mixture works well because emergence from 
anesthesia is smoother and has a high factor of safety.  Under 
anesthesia, the rat did not respond to various audible and tactic 
stimuli, and maintained a normal breathing and heart rate.  Once the 
anesthesia had taken effect and the rat was in Stage 3, it was taken out 
of the chamber to undergo prep procedures.   
 
The assistant prepped the rat by shaving the surgical site (rat’s head), 
applying depilatory cream to remove excess hair, and disinfecting the 
area with Betadine solution using sterile cotton swabs applied in a 
circular motion.  This process was preformed 3 times (with 3 different 
cotton swabs) and the antiseptic was in contact with the skin for a 
minimum of 3 minutes before incision.  The rat was put back in the 
chamber while the surgical area was prepped.   
 
The surgical area was prepped by disinfecting the table to maintain a 
clean, uncluttered, and sanitized area.  A new bench cover was placed 
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on the table and the rat was placed on top of it.    To prep for post-
operative procedures, the assistant also placed a heating pad in the 
microwave so that it was ready to heat up once the surgical 
procedures were completed.  Once the “surgeon” had scrubbed and 
put on the sterile gown, he/she put on the sterile gloves and sat down 
to begin surgery.  The assistant carefully opened the pre-sterile 
package containing the sterile surgical drape and the surgeon 
removed the drape from the packaging and placed it over the rat to 
ensure that aseptic standards were met.  With the help of the assistant, 
the other sterile packages containing the sterile instruments, butyl 
cyanoacrylate/applicator, glass slab, gauze, and cotton swabs were 
also opened while the surgeon removed the contents of those sterile 
packages and placed them onto the sterile field.  The rat was ready to 
undergo the surgical procedure.   
 
3.3.3   Operative Procedures 
Using the “tips-only” technique, the surgeon made an incision 
approximately 1 inch in length along the midline of the head from the 
eyes to the ears using firm pressure to guarantee a clean cut in a single 
stroke.  Once the incision was made, the periosteum was carefully 
folded back to expose the bony complex on the surface of the cranium. 
Sterile forceps were used to pick up one temporary anchorage device, 
contour it to fit the shape of the animal’s skull, and place it on the 
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surface of the cranial bone.  Preliminary experiments showed that only 
one 7mm diameter TAD can be successfully placed on the skull and 
covered with the periosteum.  The periosteum is too thin to effectively 
cover more than one implant.  In addition, preliminary experiments 
confirmed that a protruding length of 2mm on one side of the TAD is 
adequate for biomechanical testing but small enough to prevent the rat 
from knocking it off.   
 
The implant was then attached to the bone using the tissue glue, butyl 
cyanoacrylate, which took approximately 2 minutes to set.  The TAD 
was placed on the cranial bone such that its distance from the cranial 
surface was as close as possible, allowing for enhanced bone 
apposition and likelihood of osseointegration.  Butyl cyanoacrylate 
was evaluated during preliminary experiments and was shown to be an 
effective adhesive.  It was also determined through preliminary 
experimentation that although the curing time with UV light is less 
than the curing time without UV light, the difference is not significant 
enough to require the use of UV light for this study.  Refer to 
Appendix F for details and results of these preliminary experiments.  
 
For both the control and the rhBMP-2 treated TADs, sterile forceps 
were used to place the wetted collagen sponge on top of the implant.  
The collagen sponge was wet with saline or reconstituted rhBMP-2 
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depending if it was a control implant or not. While surgery was in 
progress, the animal’s vital signs were continually monitored.  Once 
the TAD was stable, the periosteum was folded back over the implant.  
Sterile forceps were used to hold the sides of the skin at the incision 
site together while the incision was closed using butyl cyanoacrylate.  
This completed the surgery.  The circulating heating pad was then 
heated up in the microwave for about 3-4 minutes to heat up to 37 
degrees.  
 
3.3.4    Post-Operative 
After surgery and the removal of the surgical drape, the rat was given 
a subcutaneous injection of Burprenorphine (0.01 – 0.05 mg/kg).  The 
rat was then moved to a warm area (recovery bin) where it was 
monitored during recovery.  A heating pad was used to return the 
animal’s body temperature back to normal.  Upon full recovery from 
the anesthesia, the rat was returned to its routine housing; each rat 
was caged separately.  Buprenorphine was administered 3 times a day 
for 2 days as necessary for pain management.  The rats were visually 
inspected daily post-op for infection, and a surgical record 
(procedure, date, anesthesia dose, route of administration) was 
maintained. 
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3.4        Histological Examination  
The rats were euthanized by carbon dioxide asphyxiation and a qualitative 
analysis of surface topography and the amount of the TAD surface covered 
by bone was conducted through photographs and visual inspection.  A 
comparison of surface topography and TAD coverage was made between 
the sandblasted/acid-etched/rhBMP-2 treated TAD and the control 
specimen (sandblasted and acid-etched TAD).  The results of the 
histological examination are found in Section 4.1 below.  
 
3.5       Biomechanical Testing  
3.5.1     General 
After qualitative analysis, biomechanical testing was performed 
using the In Spec, Instron Corporation, Camden, MA 
micromechanical testing system. Load was applied to the upper 
part of each temporary anchorage device in the shear direction 
with a force at constant speed until the surrounding bone was 
destroyed.   
 
3.5.2     Experimental Model 
As a proof of experimental concept, the TAD was imbedded onto 
a polyurethane 20 lb foam block and attached to the In Spec, 
Instron Corporation, Camden, MA micromechanical testing 
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system with a 50 N load cell.  Five replicate tests were conducted 
with an average shear load of 8.9 N ± 1.5 N.   
                                   
                                         Figure 3-3 – Experimental Model for Biomechanical Testing 
 
3.5.3     Test Setup for Biomechanical Testing 
 
 
                                         Figure 3-4 – Biomechanical Testing Setup 
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                                           Figure 3-5 – Applying Load to Implant 
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4.      RESULTS 
4.1     Histological Examination Results Summary 
 Visual inspection of the TADs prior to biomechanical testing showed bone 
formation on both the control TADs and the TADs treated with rhBMP-2.  
However, TADs treated with rhBMP-2 had a greater amount of bone 
coverage (enhanced osseointegration) than the control TADs.  For all but 
one of the rhBMP-2 treated TADs (exception is Rat # 10), only the 
protruding portion of the TAD was visible after 6 weeks of implantation in 
the rat’s skull as the top surface of the TAD was almost entirely covered in 
new bone.  For Rat #10, the TAD site was infected and thus had minimal 
to no bone coverage.  Table 4-1 below shows the percentage of bone 
coverage observed on each TAD for each rat.  The raw data (TAD 
photographs) can be found in Appendix G. 
 
Table 4-1 – Percent Bone Coverage on TAD 
Rat # Control or rhBMP-2 treated Percent Bone Coverage 
Rat 5 Control, sponge on top 10% 
Rat 6 Control, sponge on top 0% – TAD migrated 
Rat 7 Control, sponge on top N/A - rat died after surgery 
Rat 9 Sponge on top w/ rhBMP-2 99% 
Rat 10 Sponge on top w/ rhBMP-2 0% - TAD site is infected  
Rat 11 Sponge on top w/ rhBMP-2 90% 
Rat 19 Sponge on top w/ rhBMP-2 N/A– rat died a few days after 
surgery 
Rat 21 Control, sponge on top 10% 
Rat 22 Sponge on top w/ rhBMP-2 99% 
Rat 23 Sponge on top w/ rhBMP-2 99% 
Rat 24 Control, sponge on top 5% 
Rat 26 Sponge on top w/ rhBMP-2 N/A - Rat died one day after 
surgery 
Rat 27 Sponge on top w/ rhBMP-2 99% 
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Based on the data in Table 4-1 above, the average percentage of bone 
coverage on a control TAD was 6.25 ± 4.79% while the average 
percentage of bone coverage on an rhBMP-2 treated TAD was 97.2 ± 
4.02% (Figure 4-1).   
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                   Figure 4-1 – Avg. Percent Bone Coverage & Stdev 
 
4.2     Biomechanical Testing  
4.2.1   Results Summary 
The biomechanical testing results showed that TADs treated with 
the rhBMP-2 on top have a significantly greater failure load than 
the control TADs.  The failure load for the rhBMP-2 treated 
TADs ranged from 32.02 N – 98.39 N, whereas the failure load 
for the control TADs ranged from 0 N – 5 N.  The value of 0.96 N 
for rat #10 was excluded as the TAD site was found to be infected 
and thus inconclusive.  See details in Table 4-2 below. 
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Table 4-2 – Failure Load Data for Each Rat 
Rat # Control or rhBMP-2 treated? Failure Load 
Rat 5 Control, sponge on top Data lost but failure load observed on hand-held device was ≈ 5 N 
Rat 6 Control, sponge on top 0 N - No testing performed as TAD 
migrated during the 6 weeks 
Rat 7 Control, sponge on top N/A – rat died after surgery 
Rat 9 Sponge on top w/ rhBMP-2 88.16 N 
Rat 10 Sponge on top w/ rhBMP-2 0.96 N – TAD site is infected 
Rat 11 Sponge on top w/ rhBMP-2 32.02 N 
Rat 19 Sponge on top w/ rhBMP-2 N/A – rat died after surgery 
Rat 21 Control, sponge on top 4.99 N 
Rat 22 Sponge on top w/ rhBMP-2 98.39 N 
Rat 23 Sponge on top w/ rhBMP-2 92.92 N 
Rat 24 Control, sponge on top 2.84 N 
Rat 26 Sponge on top w/ rhBMP-2 N/A – rat died one day after surgery 
Rat 27 Sponge on top w/ rhBMP-2 68.14 N 
 
4.2.2   Mean Failure Load & Standard Deviation 
Based on the data in Table 4-2 above, the mean failure load for 
the control TADs is 3.21 N ± 2.37 N while the mean failure load 
for the rhBMP-2 treated TADs is 75.93 N ± 27.07 N (Figure 4-2 
below).   
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   Figure 4-2 – Mean Failure Load & Standard Deviation 
The failure load graphs for each rat/TAD are found in Appendix H. 
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5.      DISCUSSION OF RESULTS 
5.1     Bone Coverage on TAD 
Bone formation was observed on both the control TADs and the TADs 
treated with rhBMP-2.  Control TADs had a percentage of bone coverage 
of 6.25 ± 4.79%.  For 3 of the 4 control TADs, bone coverage was present 
as a result of its sandblasted and acid-etched surface.  As described in the 
Literature Review section of this paper, the combination of a sandblasted 
and acid-etched surface has been known to improve bone apposition. 
Based on the results, this type of microrough titanium surface does in fact 
facilitate the formation of new bone.   
 
For 1 of the control TADs, however, no bone coverage was observed as 
the implant had migrated sometime during the 6 week implantation period.  
The reason for implant migration may be due to one or a combination of 
the following: 1) the TAD was knocked loose during the 6 week 
implantation period (i.e. the rat knocked it out of place), 2) not enough 
butyl cyanoacrylate was used to glue the TAD to the bone during the rat 
surgery resulting in an unstable TAD, and 3) not enough butyl 
cyanoacrylate was used to adequately seal the surgical incision making it 
easier for the rat to knock the TAD out of place.  Without TAD stability, 
the risk of microfractures at the TAD-bone interface increases which in 
turn decreases the likelihood of osseointegration.  See Figure 5-1 below 
for the percent bone coverage summary for a control TAD.   
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         Figure 5-1 – Percent Bone Coverage Summary for Control TAD 
 
Even further, the TADs which were sandblasted, acid-etched, and treated 
with rhBMP-2, showed even more bone coverage (enhanced 
osseointegration) than the control TADs.  For all but one of the rhBMP-2 
treated TADs (exception is Rat # 10), only the protruding portion of the 
TAD was visible after 6 weeks of implantation in the rat’s skull as the top 
surface of the TAD was almost entirely covered in new bone.  
Specifically, the rhBMP-2 treated TADs had a percentage of bone 
coverage of 97.2 ± 4.02%.  Compared to a control TAD, the percent bone 
coverage on an rhBMP-2 treated TAD was significantly greater.  This 
shows that rhBMP-2 promotes enhanced osseointegration.  The 
significance of rhBMP-2 on enhancing bone formation was quantified 
during biomechanical testing which is discussed in Section 5.2 below. See 
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Figure 5-2 below for the percent bone coverage summary for an rhBMP-2 
treated TAD.   
Figure 5-2 – Percent Bone Coverage for an rhBMP-2 treated TAD 
 
As referenced above, although the TAD in Rat #10 was treated with 
rhBMP-2, visual inspection of the TAD prior to biomechanical testing 
showed minimal to no bone formation compared to the rest of the rhBMP-
2 treated TADs.  This TAD site was found to be infected, which likely 
interfered with bone formation in this area.   
 
5.2     TAD Stability 
The biomechanical testing results showed that TADs treated with the 
rhBMP-2 on top have a significantly greater failure load than the control 
TADs.  The failure load for the rhBMP-2 treated TADs ranged from 32.02 
N – 98.39 N, whereas the failure load for the control TADs ranged from 0 
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N – 5 N.  The value of 0.96 N for rat #10 was excluded from the 
calculation and analysis for the rhBMP-2 treated TADs as the TAD site 
was found to be infected and thus inconclusive.  The large range for the 
rhBMP-2 treated TADs is largely due to TAD stability (i.e. how well the 
butyl cyanoacrylate glues the TAD to the bone prior to osseointegration or 
how well the TAD contours to the rat’s skull).  The more stable the TAD, 
the better chance for enhanced osseointegration.  On average, the amount 
of force required to pull an rhBMP-2 treated TAD from the bone was 
75.93 N ± 27.02 N.  See Figure 5-1 below for the failure load summary for 
an rhBMP-2 treated TAD.  This average does not include the data for Rat 
#10.   
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         Figure 5-3 – Failure Load Summary for rhBMP-2 Treated TAD           
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In contrast, the average amount of force required to pull a control TAD 
from the bone was 3.21 N ± 2.37 N.  See Figure 5-2 below for the failure 
load summary for a control TAD.  This average includes the data for Rat 
#6, which is 0 N since the TAD migrated sometime during the 6 week 
timeframe.  If 0 N was removed as a data point based on the assumption 
that osseointegration would have occurred had the TAD been stable, then 
the average failure load would be 4.23 N ± 1.24 N.  
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Figure 5-4 – Failure Load Summary for Control TAD 
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6.     CONCLUSIONS 
Based on the visual inspection and biomechanical testing results, sandblasted and 
acid-etched temporary anchorage devices (TADs) treated with recombinant human bone 
morphogenetic protein-2 (rhBMP-2) promote better osseointegration than TADs that are 
only sandblasted and acid-etched. Specifically, TADs treated with rhBMP-2 showed an 
increase in bone formation (avg. of 97.2% TAD surface covered by bone vs. avg. of 
6.25% TAD surface covered by bone) and an increase in total TAD stability, or adhesion 
strength at the bone-to-TAD interface (avg. of 75.93 N vs. avg. of 3.21 N).  
 
By promoting enhanced osseointegration, rhBMP-2 helps the TADs serve as 
stable anchors while avoiding puncture of the bone.  In addition, butyl cyanoacrylate 
plays a key role in providing TAD stabilization until osseointegration can be achieved.  
As evident in the results, TADs which have become loose or migrated early in the 
implantation stages will have minimal or no osseointegration.  With the use of TADs as 
stable anchors, teeth movement can be controlled without causing movement to the 
surrounding teeth and with enhanced bone formation at the TAD site, this eliminates the 
need for direct insertion through the gingival tissue and into the bone which reduces the 
chances of developing bone infections. These characteristics can provide a significant 
clinical benefit for orthodontic patients.   
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Appendix A 
Rat Surgery Details from Lab Notebook 
Table A-1 – Rat Surgery Details 
Rat # Date Sponge Type Time Action 
5 10/3/2008 Control, sponge 
on top 
8:00pm IP injection of 0.22cc Ketamine 
and 0.25cc Xylazine 
Subcutaneous injection of 
0.0495cc Buprenorphine and 15cc 
saline 
   8:08pm Apply 0.09cc saline on collagen 
sponge 
   8:09pm Start incision 
   8:39pm Surgery completed 
   9:51pm Rat movement; began recovery 
from anesthesia 
 10/4/2008  6:20am Subcutaneous injection of 
0.0495cc Buprenorphine  
 11/15/2008  5:30pm Euthanized by CO2 asphyxiation 
     
6 10/3/2008 Control, sponge 
on top 
9:00pm IP injection of 0.18cc Ketamine 
and 0.21cc Xylazine 
Subcutaneous injection of 0.04cc 
Buprenorphine and 15cc saline 
   9:05pm Apply 0.09cc saline on collagen 
sponge 
   9:13pm Start incision 
   9:45pm Surgery completed 
   10:54pm Rat movement; began recovery 
from anesthesia 
 10/4/2008  6:25am Subcutaneous injection of 0.04cc 
Buprenorphine  
 11/15/2008  5:30pm Euthanized by CO2 asphyxiation 
     
7 10/3/2008 Control, sponge 
on top 
9:30pm IP injection of 0.16cc Ketamine 
and 0.18cc Xylazine 
Subcutaneous injection of 0.04cc 
Buprenorphine and 15cc saline 
   9:45pm Additional IP injection of 0.10cc 
Ketamine and 0.10cc Xylazine 
   10:00pm Additional IP injection of 0.15cc 
Ketamine and 0.17cc Xylazine 
   10:20pm Additional IP injection of 0.16cc 
Ketamine and 0.18cc Xylazine 
   10:25pm Apply 0.09cc saline on collagen 
 36 
Rat # Date Sponge Type Time Action 
sponge 
   10:30pm Start incision 
   10:50pm Surgery completed 
   11:45pm Rat movement; began recovery 
from anesthesia 
 10/4/2008  6:30am Subcutaneous injection of 0.04cc 
Buprenorphine  
 10/8/2008  Unknown Rat dies a few days after surgery 
     
9 10/4/2008 Sponge on top 
with rhBMP-2 
7:13am IP injection of 0.19cc Ketamine 
and 0.22cc Xylazine 
Subcutaneous injection of 0.044cc 
Buprenorphine and 15cc saline 
   7:27am Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   7:32am Start incision 
   7:45am Surgery completed 
   8:45am Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:05am Subcutaneous injection of 0.044cc 
Buprenorphine  
 11/15/2008  5:45pm Euthanized by CO2 asphyxiation 
     
10 10/4/2008 Sponge on top 
with rhBMP-2 
7:45am Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   7:52am IP injection of 0.20cc Ketamine 
and 0.23cc Xylazine 
Subcutaneous injection of 0.046cc 
Buprenorphine and 15cc saline 
   8:02am Start incision 
   8:05am Additional IP injection of 0.10cc 
Ketamine and 0.10cc Xylazine 
   8:21am Surgery completed 
   9:30am Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:08am Subcutaneous injection of 0.044cc 
Buprenorphine  
 11/15/2008  5:50pm Euthanized by CO2 asphyxiation 
     
11 10/4/2008 Sponge on top 
with rhBMP-2 
8:19am Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   8:28am IP injection of 0.18cc Ketamine 
and 0.20cc Xylazine 
Subcutaneous injection of 0.041cc 
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Rat # Date Sponge Type Time Action 
Buprenorphine and 15cc saline 
   8:36am Start incision 
   8:37am Additional IP injection of 0.10cc 
Ketamine and 0.10cc Xylazine 
   9:00am Surgery completed 
   10:00am Rat movement; began recovery 
from anesthesia 
 10/5/2008  8:10am Subcutaneous injection of 0.044cc 
Buprenorphine  
 11/15/2008  5:50pm Euthanized by CO2 asphyxiation 
     
19 10/4/2008 Sponge on top 
with rhBMP-2 
9:33pm Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   9:48pm IP injection of 0.20cc Ketamine 
and 0.23cc Xylazine 
Subcutaneous injection of 
0.0454cc Buprenorphine and 15cc 
saline 
   10:04pm Start incision 
   10:22pm Surgery completed 
 10/8/2008  Unknown Rat dies a few days after surgery 
     
21 10/5/2008 Control, sponge 
on top 
9:08am IP injection of 0.16cc Ketamine 
and 0.19cc Xylazine 
Subcutaneous injection of 
0.0371cc Buprenorphine and 15cc 
saline 
   9:30am Apply 0.09cc saline on collagen 
sponge 
   9:32am Start incision 
   9:50am Surgery completed 
   11:10am Rat movement; began recovery 
from anesthesia 
 10/6/2008  8:08am Subcutaneous injection of 
0.0371cc Buprenorphine  
 11/15/2008  6:30pm Euthanized by CO2 asphyxiation 
     
22 10/5/2008 Sponge on top 
with rhBMP-2 
9:40am IP injection of 0.20cc Ketamine 
and 0.22cc Xylazine 
Subcutaneous injection of 
0.0446cc Buprenorphine and 15cc 
saline 
   9:41am Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
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Rat # Date Sponge Type Time Action 
   9:58am Start incision 
   10:18am Surgery completed 
   11:45am Rat movement; began recovery 
from anesthesia 
 10/6/2008  8:10am Subcutaneous injection of 
0.0446cc Buprenorphine  
 11/15/2008  6:35pm Euthanized by CO2 asphyxiation 
     
23 10/5/2008 Sponge on top 
with rhBMP-2 
10:10am IP injection of 0.16cc Ketamine 
and 0.18cc Xylazine 
Subcutaneous injection of 
0.0364cc Buprenorphine and 15cc 
saline 
   10:44am Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   10:45am Start incision 
   10:18am Surgery completed 
   11:11am Rat movement; began recovery 
from anesthesia 
 10/6/2008  8:15am Subcutaneous injection of 
0.0364cc Buprenorphine  
 11/15/2008  6:35pm Euthanized by CO2 asphyxiation 
     
24 2/7/2009 Control, sponge 
on top 
3:30pm IP injection of 0.22cc Ketamine 
and 0.22cc Xylazine 
Subcutaneous injection of 
0.0446cc Buprenorphine and 15cc 
saline 
   3:40pm Apply 0.09cc saline on collagen 
sponge 
   3:45pm Start incision 
   4:10pm Surgery completed 
   5:00pm Rat movement; began recovery 
from anesthesia 
 2/8/2009  8:20am Subcutaneous injection of 
0.0446cc Buprenorphine  
 3/21/2009  2:30pm Euthanized by CO2 asphyxiation 
     
26 2/7/2009 Sponge on top 
with rhBMP-2 
4:55pm IP injection of 0.25cc Ketamine 
and 0.24cc Xylazine 
Subcutaneous injection of 
0.0465cc Buprenorphine and 15cc 
saline 
   5:10pm Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
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Rat # Date Sponge Type Time Action 
   4:15pm Start incision 
   4:10pm Surgery completed 
   5:20pm Rat movement; began recovery 
from anesthesia 
 2/8/2009  Unknown Rat dies a day after surgery 
     
27 2/7/2009 Sponge on top 
with rhBMP-2 
9:50pm IP injection of 0.25cc Ketamine 
and 0.24cc Xylazine 
Subcutaneous injection of 
0.0465cc Buprenorphine and 15cc 
saline 
   9:57pm Apply 0.09cc reconstituted BMP-2 
on collagen sponge 
   10:10pm Start incision 
   10:50pm Surgery completed 
   12:30am Rat movement; began recovery 
from anesthesia 
 2/8/2009  8:30am Subcutaneous injection of 
0.0465cc Buprenorphine 
 3/21/2009  2:30pm Euthanized by CO2 asphyxiation 
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Appendix B 
Preliminary Experiment Using One Rat 
One rat was used to determine the following: 
1. Effectiveness of anesthesia 
A mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine, 
10 mg/kg body weight of Xylazine) should be used for inducing general 
anesthesia. The source used to determine these dosages is Lumb and Jones 
Veterinary Anesthesia and Analgesia, 4th Ed. by W. J. Tranquilla.  In addition, a 
dose of Buprenorphine should be administered subcutaneously (0.01-0.05 mg/kg) 
between the shoulder blades to mitigate pain [24].  The Ketamine/Xylazine 
mixture provides approximately 30 minutes of effective anesthesia, and a ½ dose 
must be available to continue the anesthesia if the surgery takes longer than 
expected.  The Ketamine/Xylazine and Buprenorphine mixture works well 
because emergence from anesthesia is smoother and it has a high factor of safety. 
The reason why the Ketamine/Xylazine and Buprenorphine mixture is chosen 
over an inhalant anesthetic, such as Halothane, is because Halothane requires that 
the rats wear a mask during surgery. Unfortunately, this mask would interfere 
with the surgical site, and therefore the Ketamine/Xylazine and Buprenorphine 
mixture is the better choice.   
 
2. Instrumentation needed 
Tray for BMP-2 procedures, BMP-2 / ACS (already prepared with center 
hole on ACS and sterilized), syringes, forceps, fine forceps, ultrafine forceps, 
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weight boat, bench covers, sterile gowns, scrubs, mask, rat gloves, nitrile gloves, 
sterile gloves, Ketamine, Xylazine, Buprenorphine, shaver, depilatory cream 
(Veet®), Betadine solution, Petri dish with saline, surgical drapes, scissors, 
scalpel, butyl cyanoacrylate / applicator, glass slab for butyl, head cap, cotton 
gauze and swabs (both sterile and non-sterile), disposable bag for blood and 
contaminated items, heating pad, recovery bin, etc. 
 
3. Preparation / Surgical procedures 
 A clean, uncluttered, and sanitized work surface should be used for prep 
and surgery.  Aseptic procedures must be followed:   
 
            Pre-operative:   
a. Sterilize instruments (using the method of heat sterilization) needed for 
prep and surgery: tray for rhBMP-2 procedures, forceps, fine forceps, 
ultrafine forceps, scissors, scalpel, butyl cyanoacrylate applicator, glass 
slab for butyl, surgical drapes, syringes, gloves, Petri dish with saline, 
cotton gauze, and cotton swabs. 
b. Bring to surgical suite: sterile instruments mentioned above as well as 
butyl cyanoacrylate, tupperware for weighing the rat, isolation mask and 
cap, sterile gowns, bench covers, weight boat, and rat in the cage. 
c. Obtain in surgical suite: Ketamine, Xylazine, Buprenorphine, scrubs, rat 
gloves, nitrile gloves, sterile gloves, shaver, depilatory cream (Veet®), 
Betadine solution, disposable bag for blood and contaminated items, 
heating pad, recovery bin, and non-sterile cotton swabs and gauze. 
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d. In an area of the surgical suite, separate from the prep and surgery area, an 
assistant must wash their hands, put on sterile gloves, and do the 
following: 1) take a 1 cm x 1 cm absorbable collagen sponge with sterile 
forceps and wet it with 0.09 cc of saline (for a control TAD) or 0.09cc of 
reconstituted rhBMP-2 (for an rhBMP-2 treated TAD) using a syringe and 
a sterile tray, and 2) let it stand for at least 15 minutes before use. 
Meanwhile, continue with the following pre-operative procedures. 
e. Weigh the animal in a weight boat to determine the appropriate dosages of 
Ketamine, Xylazine, and Buprenorphine.  The amount of anesthesia given 
to a rat is determined by the following criteria: 44 mg/kg body weight of 
Ketamine, 10 mg/kg body weight of Xylazine, and 0.01 – 0.05 mg/kg 
body weight of Buprenorphine.  Record the dosages in the lab notebook. 
f. Place a bench cover down on the table. 
g. Put on rat gloves and grab the animal around the torso to administer the 
anesthesia.  Use a mixture of Ketamine and Xylazine (44 mg/kg body 
weight of Ketamine, 10 mg/kg body weight of Xylazine) for inducing 
general anesthesia.  This will provide approximately 30 minutes of 
effective anesthesia. 
h. In addition, administer a dose of Buprenorphine subcutaneously (0.01 – 
0.05 mg/kg body weight) between the shoulder blades.  The 
Ketamine/Xylazine and Buprenorphine mixture works well because 
emergence from anesthesia is smoother and has a high factor of safety.  
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Place the rat in a chamber until the anesthesia takes effect and the animal 
is down. 
i. Throw out the bench cover and place a new one for prepping.  An assistant 
will start the prepping of the animal while the individual performing the 
surgery starts the surgical scrub and puts on a sterile gown to prepare for 
surgery. 
j. Assistant: put scrubs and nitrile gloves on for prepping procedures. 
k. Take the rat out of the chamber and place on the bench cover.  Use the 
clippers provided in the surgical suite to shave the surgical site (rat’s 
head).  Then, apply depilatory cream on the surgical site.  Wait a few 
minutes for the depilatory cream to set. Rub the surgical site with a damp 
2 x 2 cotton sponge to remove excess hair.     
l. Pour Betadine antiseptic solution on a swab and apply it to the rat’s head 
in a circular motion.  Repeat a minimum of 3 times.  Put the animal back 
in the chamber. 
m. Throw away the bench cover.  
n. Disinfect the table to maintain a clean, uncluttered, and sanitized area.  
Use gauze sponge to wipe it down. 
o. Place down a new bench cover. 
p. Put the rat down on the new bench cover. 
q. Take off nitrile gloves and wash hands. 
r. Take pre-sterile surgical packages with surgical drape and sterile 
instruments, sterile gloves, isolation mask and cap, butyl 
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cyanoacrylate/applicator, glass slab, gauze, and cotton swabs and place 
them on the table within reach of the individual performing surgery. 
s. Put the heating pad in the microwave so it is ready to heat up once surgical 
procedures are completed. 
t. Open up the sterile surgical package cover, and open up covering for 
sterile instruments (without touching the actual instruments). 
u. Once the “surgeon” has scrubbed and put on the sterile gown, he/she must 
put on the sterile gloves and sit down to begin surgery. 
v. The surgeon should now pull out the surgical drape from the sterile 
surgical packages and place it on the animal.  Use forceps and scissors to 
cut drape at incision site. Use other forceps and scissors to do actual 
incision (internal work). 
 
Operative: 
a. Begin surgery with sterile instruments and handle instruments aseptically. 
b. Using the “tips-only” technique, make an incision along the line from the 
middle of the eyes to the middle of the ears.   
c. Once the incision is made, carefully fold back the periosteum using sterile 
instruments (i.e. scalpel, forceps, etc.). 
d. When the bony complex on the surface of the cranium is exposed, use 
sterile forceps to pick up a titanium implant, contour it to fit the skull 
shape, and place it on the bony complex.  With the help of an assistant, 
glue the implant to the bone with butyl cyanoacrylate.  Wait 
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approximately 2 minutes to set.  Use a sterile instrument to place the 
collagen sponge on top of the implant. The collagen sponge will be soaked 
in saline or rhBMP-2 depending on whether it is a control implant or not.  
e. While surgery is in progress, continually monitor the animal’s vital signs.   
f. Once the implant is stable, place as much of the periosteum over the 
implant.   
g. Use sterile forceps to hold the sides of skin at the incision site together 
while an assistant closes the incision site using butyl cyanoacrylate.  At 
this point, have another assistant go to the microwave to heat up the 
circulating heating pad for about 3-4 minutes to heat up to 37 degrees. 
 
Post-Operative: 
a. Remove the surgical drape. 
b. Give the rat a subcutaneous injection of Buprenorphine (0.01 - 0.05 
mg/kg). 
c. Move the rat to a warm area (recovery bin) to return its body temperature 
back to normal.  In the recovery bin, place the rat on a blue bench cover, 
above a heating pad, to allow it to recover.  Return the animal to its 
routine housing only after full recovery from anesthesia.  Each rat will be 
caged separately. 
d. Buprenorphine (0.01 -0.05 mg/kg) should be administered 3 times a day 
for 2 days as necessary for pain management.  In the event of an infection, 
the wound site will be cleaned 2 times/day with Betadine solution. 
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e. The rats will be visually inspected daily post-op for infection.  A surgical 
record (procedure, date, anesthesia dose, route of administration) will be 
maintained. 
 
4. Surgical site to least elicit blood flow, angulations, and location of incision 
The incision should be made in such a way that it elicits the least amount 
of blood flow. In terms of the vascular structures in a rat, the common carotid 
artery splits into the internal and external carotid arteries ventral to the auditory 
bulla (bony capsule enclosing the middle and inner ear). The internal carotid 
artery moves anteriorly to supply blood to the brain and the external carotid artery 
moves anteriorly to supply blood to most of the structures of the head.  To avoid 
compromising the rat’s vascular system, an incision approximately 1 inch in 
length should be made along the midline of the skull. The midline incision in the 
scalp should be made using firm pressure to guarantee a clean cut in a single 
stroke. The incision should be made from the area between the eyes to the area 
between the ears. Then, once the incision is made, the periosteum can be carefully 
removed. The periosteum can be pulled back and removed from the skull using 
scalpel, forceps and scissors. 
 
5. Implant contour, adhesion method, and incision site closure  
The site(s) should be chosen such that the TAD follows the contour of the 
skull in the best way possible. The TAD should be placed on the cranial bone 
such that its distance from the cranial surface is as close as possible.  Only one 
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implant can be successfully placed on the skull and covered with the periosteum. 
The periosteum is too thin and does not sufficiently cover two implants at one 
time.  Therefore, only one implant will be used for each rat.  Butyl cyanoacrylate 
will be used to ensure the adhesion of the implant to the bone and for closure of 
the incision. 
 
6. Implant size and protruding length 
One 7 mm diameter TAD can fit on one rat skull.  A protruding length of 
2 mm on one side is sufficient enough for biomechanical testing and small enough 
to prevent the rat from knocking it off.  The surgical procedures should be purely 
subcutaneous so that the protruding part of the implant will be under the skin. 
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Appendix C 
Surgery Checklist  
Date____________                        Rat Skull Surgery                      Initials____________  
 
Rat Information 
Breed: _______________ 
Sex:  ________________ 
Weight: ______________ 
Tag: _________________ 
Cage: ________________ 
 
Materials 
Sterilized Instruments 
___1.   forceps 
___2.   fine forceps 
___3.   ultrafine forceps 
___4.   scissors 
___5.   scalpel 
___6.   cotton gauze 
___7.   cotton swabs 
 
Bring to Surgical Suite 
___8.   sterile surgical drapes 
___9.   sterile syringes 
___10.   butyl cyanoacrylate/applicator/glass slab 
___11.   sterile gown, mask and cap 
___12.   bench covers 
___13.   weight boat 
 
Obtained in Surgical Suite 
___14.   anesthesia (Ketamine and Xylazine) 
___15.   analgesic (Buprenorphine) 
___16.   scrubs 
___17.   rat gloves 
___18.   sterile gloves 
___19.   shaver 
___20.   depilatory cream (Veet®) 
___21.   Betadine solution 
___22.   disposable bag for blood and contaminated items 
___23.   heating pad 
___24.   recovery bin 
___25.   non-sterile cotton swabs  
___26.   non-sterile cotton gauze 
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rhBMP-2/ACS Preparation or Saline/ACS Preparation 
___27. Take a 1 cm x 1 cm absorbable collagen sponge and wet it with 0.09cc of saline 
(for a control TAD) or 0.09 cc of  
   reconstituted rhBMP-2. 
___28.   Let collagen sponge stand for at least 15 minutes before use. 
 
Surgery Preparation 
___29.   Weigh animal in weight boat. 
___30.   Put on rat gloves and grab animal around torso to administer anesthesia. Use a  
   mixture of Ketamine and Xylazine (44 mg/kg body weight of Ketamine, 10  
   mg/kg body weight of Xylazine).  Record dosages in the lab notebook.  
___31.   Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg  
   body weight). Record dosage in the lab notebook.  
___32.   Place rat in chamber (anesthesia box) to let the anesthesia take effect. 
___33.   Surgeon: put on mask/cap, perform surgical scrub, and put on sterile gown and    
              gloves to prepare for surgery. 
___34.   Assistant: put scrubs and nitrile gloves on.  Perform prepping procedures below. 
___35.   Place bench cover on table for preparation procedures. 
___36.   Take rat out of chamber and place on bench cover. 
___37.   Shave hair on surgical site (rat’s head) using clippers. 
___38.   Apply depilatory cream to surgical site and wait a few minutes. 
___39.   Rub surgical site with a damp 2 x 2 cotton sponge to remove excess hair. 
___40.   Apply Betadine solution on the rat’s head a minimum of 3 times in a circular  
              motion. 
___41.   Return rat to chamber.  
___42.   Throw away bench cover. 
___43.   Disinfect table. Use gauze to wipe it down. 
___44.   Place down a new bench cover. 
___45.   Put the rat down on the new bench cover. 
___46.   Take off nitrile gloves and wash hands. 
___47.   Place pre-sterile surgical packages (with sterile drape), sterile instruments, sterile  
   gloves, and isolation mask and cap on the table. 
___48.   Place heating pad in microwave so it is ready to heat up once surgery is done. 
___49.   Put on mask and cap. 
___50.   Open up sterile surgical packages (sterile drape and instruments) without    
              touching the inside of the sterile packages. 
 
Surgery 
___51.   Surgeon: pull out sterile surgical drape from sterile package and put over rat.     
              Perform surgery procedures below. 
___52.   Use forceps and scissors to cut drape at incision site. 
___53.   Make an incision along the midline of the rat’s head, from the middle of the eyes  
   to the middle of the ears. 
___54.   Carefully fold back the periosteum using forceps. 
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___55.   Use sterile forceps to pick up a titanium implant and contour it to fit the shape of  
   the skull. 
___56.   Place implant on bony complex. 
___57.   With the help of an assistant, glue implant to bone with butyl cyanoacrylate.  
   Let it set for about 2 minutes. 
___58. Use a sterile instrument to place the collagen sponge/rhBMP-2 or collagen 
sponge/saline on top of the implant. 
___59.   Close the incision using butyl cyanoacrylate.  At this time, have an assistant                   
              microwave the heating pad for about 45 seconds. 
 
Post-Surgical 
___60.   Remove surgical drape. 
___61.   Give the rat a subcutaneous injection of Buprenorphine (0.01 – 0.05 mg/kg). 
___62.   Place rat in recovery bin, on a blue bench cover, above a heating pad to allow to 
   recover. 
___63.   Return rat to its routine housing only after full recovery from anesthesia. Each  
   rat will be caged separately. 
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Appendix D 
Preliminary Experiment Using INFUSE® Bone Graft Sample Kit 
Note: A buffer was used to substitute for the rhBMP-2 in the sample kit 
Questions to be answered from the experiment: 
• Is it possible or necessary to separate the rhBMP-2 and sterile water into separate 
vials for smaller samples? If so, how should this be done? 
• Is the effectiveness of the rhBMP-2 / sterile water mixture compromised if it is 
not used all at one time? 
• What tools are necessary to cut the absorbable collagen sponge (ACS) into its 
desired shape?  
• Should the collagen sponge be cut before or after the rhBMP-2 / sterile water 
mixture is applied to it? 
• How much ACS is need for one implant?  
• 4.0 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen sponges. 
How much of the reconstituted rhBMP-2 is needed for just 1 collagen sponge? ½ 
of a collagen sponge? Etc.? 
• How can a hole be created in the middle of the shaped sponge for the protruding 
part of the implant? 
• Since the kit states that the wet collagen sponges must be used within 2 hours, 
how many rats can undergo surgery within 2 hours with the assumption that the 
sponges will be prepared before the surgeries begin?  
 
Experimental procedure 
• Take a 10 mL syringe out into the field, and draw 8.4 mL of sterile water into the 
syringe. 
• Inject 8.4 mL of sterile water into the buffer powder vial and swirl the vial to 
ensure adequate mixing. 
• Open the collagen sponge package and take out one of the collagen sponges. 
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• Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3 collagen 
sponges, calculate the amount of mixture needed for 1 collagen sponge: 4 mL / 3 
sponges = 1.33 mL / sponge. 
• Use another 10 mL syringe to withdraw 1.33 mL of reconstituted rhBMP-2 from 
the vial. 
• Uniformly distribute 1.33 mL of reconstituted rhBMP-2 on 1 of the 2.5 cm x 5 cm 
collagen sponges.  
• Allow the wet collagen sponge to stand for 15 minutes. 
• After 15 minutes, use 2 different tools to cut the collagen sponge in the shape of 
the implant. 
• Place a sample implant on the collagen sponge and used an x-acto knife to cut 
around the outer edge of the implant. 
• Using another section of the collagen sponge, use a 1-hole punch to punch a hole 
through the wet sponge. 
• Take out a second collagen sponge. This time, cut the non-wetted sponge with the 
x-acto knife. Likewise, use the 1-hole punch on the non-wetted sponge. 
 
Results and Conclusions of Preliminary Experiment 
• It is not necessary to separate the rhBMP-2 and sterile water into smaller vials.  
As long as the reconstituted rhBMP-2 is refrigerated, it can be used at another 
point in time.  The effectiveness of the rhBMP-2 / sterile water mixture is not 
compromised if it is not used all at once. The kit instructions state that the wet 
collagen sponge must be used within 2 hours, but there is nothing stating that the 
rhBMP-2 / sterile water mixture must be used within 2 hours.  
• The 1-hole punch is not a good tool for the purposes of this study because it 
punches out a diameter that is smaller than the diameter of the implant for both 
the non-wetted and wet sponge.  
• It is difficult to cut a circular shape with the x-acto knife on a wet sponge. 
However, the x-acto knife works better when making straight cuts on the wet 
sponge.  
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• It is difficult to cut a circular shape through a non-wetted sponge with the x-acto 
knife, but easy to cut straight lines.  
• Cutting the non-wetted sponge is easier than cutting the wet sponge. 
• A 1.00 cm x 1.25 cm section (1/10 of 1 collagen sponge) of a non-wetted sponge 
is needed for 1 implant. Once the sponge is wet, it can be shaped circularly to 
follow the shape of the implant.  
• The successful way of applying the collagen sponge to the implant: 
1. Cut one non-wetted collagen sponge (2.5 cm x 5 cm) into 10 equal 
sections (1.00 cm x 1.25 cm). 
 
Figure D-1 – Collagen Sponge Dimensions 
Note:  Figure not drawn to scale 
 
2. Use a plastic head pushpin to create a hole in the center of one 1.00 cm x 
1.25 cm piece for the protruding part of the implant.  
3. Apply the rhBMP-2 / sterile water mixture to that same 1.00 cm x 1.25 cm 
section. Since 4 mL of the rhBMP-2 / sterile water mixture is needed for 3 
collagen sponges, the amount of mixture needed for 1 collagen sponge is 4 
mL / 3 sponges = 1.33 mL / sponge.  However, since one collagen sponge 
is divided into 10 equal sections, 1/10 * 4/3 = 0.133 mL of the rhBMP-2 / 
sterile water mixture is needed per section.  The syringe given in the kit is 
a 10 mL syringe with increments of 0.2 mL.  For better accuracy, use a 
smaller syringe with smaller increments. 
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4. After waiting at least 15 minutes, place the wet collagen sponge over the 
implant and shape the collagen sponge into a circular form (which follows 
the shape of the implant).   
• Since the wet collagen sponge must be used within 2 hours, only wet a 1.00 cm x 
1.25 cm section of absorbable collagen sponge before each rat goes through 
surgery. 
• Note: the collagen sponge pieces used during the actual surgery were different in 
size than those used during the experimental phase.  Specifically, 1 cm x 1 cm 
pieces were used with 0.09 cc of reconstituted rhBMP-2. 
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Appendix E 
Anesthetics/Analgesics 
Bottle Concentrations (mg/mL) 
Ketamine HCl: 100 mg/mL 
Xylazine: 20 mg/mL 
Buprenorphine HCl: 0.3 mg/mL 
 
Dosage (mg/kg of body weight) 
Ketamine HCl: 44 mg/kg 
Xylazine: 10 mg/kg 
Buprenorphine HCl: 0.03 mg/kg 
 
Table E-1 - Number of mL Administered of Each Drug Based on Weight 
Weight of Rat (g) Weight of Rat (kg) Ketamine (mL) Xylazine (mL) Buprenorphine (mL) 
200 0.200 0.088 0.100 0.020 
205 0.205 0.090 0.103 0.021 
210 0.210 0.092 0.105 0.021 
215 0.215 0.095 0.108 0.022 
220 0.220 0.097 0.110 0.022 
225 0.225 0.099 0.113 0.023 
230 0.230 0.101 0.115 0.023 
235 0.235 0.103 0.118 0.024 
240 0.240 0.106 0.120 0.024 
245 0.245 0.108 0.123 0.025 
250 0.250 0.110 0.125 0.025 
255 0.255 0.112 0.128 0.026 
260 0.260 0.114 0.130 0.026 
265 0.265 0.117 0.133 0.027 
270 0.270 0.119 0.135 0.027 
275 0.275 0.121 0.138 0.028 
280 0.280 0.123 0.140 0.028 
285 0.285 0.125 0.143 0.029 
290 0.290 0.128 0.145 0.029 
295 0.295 0.130 0.148 0.030 
300 0.300 0.132 0.150 0.030 
305 0.305 0.134 0.153 0.031 
310 0.310 0.136 0.155 0.031 
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315 0.315 0.139 0.158 0.032 
320 0.320 0.141 0.160 0.032 
325 0.325 0.143 0.163 0.033 
330 0.330 0.145 0.165 0.033 
335 0.335 0.147 0.168 0.034 
340 0.340 0.150 0.170 0.034 
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Appendix F 
Butyl Cyanoacrylate and the Effect of UV Light on Curing Time 
 In the presence of moisture, cyanoacrylates rapidly polymerize and set quickly. A 
quick and easy way to test whether a certain type of cyanoacrylate will adhere to tissue 
with degrees of moisture is to apply the cyanoacrylate to designated sections of the 
implant and see if it adheres to cow bone or fresh meat from the grocery store.  The tissue 
found in cow bone is similar to the tissue found in rats, and therefore using the cow bone 
allows for quick and effective testing without having to perform surgery on the rat for 
this preliminary step. In addition, saliva added to the site of the implant accounts for the 
presence of blood during the actual surgery. This aids in determining whether the saliva, 
with chemical and physical components somewhat similar to blood, will have any effect 
on the implant’s ability to adhere. From this experiment, the curing time and whether the 
cyanoacrylate is an effective adhesive can be determined. Moreover, the effect of UV 
light (which has been known to reduce curing time) will also be evaluated. Finding a way 
to reduce the curing time is desired to ensure implant stability and to minimize the 
amount of blood flow and other fluids into the implant site.  
 
 An experiment using Vetbond butyl cyanoacrylate was performed.  The results 
from the experiment can be found in the following table:  
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Table F-1 – Vetbond Butyl Cyanoacrylate Curing Time 
 
 
 
 
 
 
 
 
 
 
 
 
The curing time was determined based on the following graphs: 
% Adhesion Strength vs. Curing Time 
(cow bone, no UV light)
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Figure F-1 – Curing Time Using Cow Bone without UV Light 
All trials used saliva to account for the presence of blood 
 
Curing Time 
Without UV 
Light 
(Trial 1) 
Curing Time 
Without UV 
Light 
(Trial 2) 
Curing Time 
With UV 
Light 
(Trial 1) 
Curing Time 
With UV 
Light 
(Trial 2) 
Cow 
Bone 
 
2 minutes 2 minutes 1 minute, 50 
seconds 
1 minute, 55 
seconds 
New 
York 
Steak 
Bone In 
(Shaved 
Bone) 
2 minutes 2 minutes 1 minute, 50 
seconds 2 minutes 
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% Adhesion Strength vs. Curing Time 
(NY steak, no UV light)
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Figure F-2 – Curing Time Using NY Steak without UV Light 
 
 
% Adhesion Strength vs. Curing Time 
(cow bone, UV light)
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Figure F-3 – Curing Time Using Cow Bone with UV Light 
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% Adhesion Strength vs. Curing Time 
(NY steak, UV light)
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Figure F-4 – Curing Time Using NY Steak with UV Light 
 
 
Several conclusions were made from the above experiment: 
• Butyl cyanoacrylate is an effective adhesive. 
• Saliva does not affect the ability of the implant to adhere to bone.  Thus, blood,  
with chemical and physical components somewhat similar to blood, is also     
assumed to have little effect on the ability of the implant to adhere to bone.    
• The curing time with UV light is less than the curing time without UV light.  
      However, the difference is not that significant. 
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Appendix G 
Bone Coverage Raw Data 
Table G-1 – Photographs of TAD Bone Coverage for Each Rat 
Rat # Control or rhBMP-2 treated 
Bone Coverage 
(Photo taken prior to biomechanical 
testing) 
Rat 5 Control, sponge on top 
 
Rat 6 Control, sponge on top No bone coverage observed – TAD 
migrated 
Rat 7 Control, sponge on top N/A - rat died after surgery 
Rat 9 Sponge on top w/ rhBMP-2 
 
Rat 10 Sponge on top w/ rhBMP-2 
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Rat 11 Sponge on top w/ rhBMP-2 
 
Rat 19 Sponge on top w/ rhBMP-2 N/A– rat died a few days after surgery 
Rat 21 Control, sponge on top 
 
Rat 22 Sponge on top w/ rhBMP-2 
 
Rat 23 Sponge on top w/ rhBMP-2 
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Rat 24 Control, sponge on top 
 
Rat 26 Sponge on top w/ rhBMP-2 N/A - Rat died one day after surgery 
Rat 27 Sponge on top w/ rhBMP-2 
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Appendix H 
Biomechanical Testing Failure Load Graphs 
 
Note:  No graphs are available for Rats 5, 6, 7, 19, 26.  See explanation in the Results 
Summary table in Section 4.2.1. 
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Figure H-1:  Failure Load for Rat #9 
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Figure H-2:  Failure Load for Rat #10 
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Figure H-3:  Failure Load for Rat #11 
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Figure H-4:  Failure Load for Rat #21 
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Figure H-5:  Failure Load for Rat #22 
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Figure H-6:  Failure Load for Rat #23 
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Rat 24
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Figure H-7:  Failure Load for Rat #24 
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Figure H-8:  Failure Load for Rat #27 
 
 
 
 
